FDA to Consider Regadenoson
CV Therapeutics has announced it will file a new drug application to the FDA for its regadenoson agent in mid-2007 following positive results from a late-stage trial, the Associated Press reported Monday.
Regadenoson is used in myocardial perfusion imaging studies, or studies on coronary artery disease. CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies.
If regadenoson is approved by the FDA, Astellas Pharma US Inc. will control its commercial sale in the U.S., and CV Therapeutics will hold retail rights to the drug outside of North America.
More like this
- Bristol-Myers, ImClone say Erbitux combination fails primary goal
- ZETIA, VYTORIN Makers Merck, Schering-Plough Merge in $41.1 Billion Deal
- Rollout of New Oral Anticoagulants Will Drastically Change Clinical Practice
- Celladon Completes $43 Million Financing to Advance Mydicar for the Treatment of Heart Failure
- GE Acquires Biomedical, Pharmaceutical Research Group